IMBdx, Inc.
KKRX:4610302,495.00
KRW
-45.00
(-1.77%)
ISIN
KR7461030009
Return %
Stock
S&P 500
1Y
-76.44
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Tae-Yu Kim
- Full Time Employees
- 65
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- BYC Highcity Bldg A Seoul SL South Korea 08506
- IPO Date
- Apr 3, 2024
- Website
- imbdx.com
- Similar Companies
- Business
- IMBdx Inc (461030.KQ) develops and commercializes liquid biopsy platforms for precision oncology diagnostics in South Korea. The company offers the AlphaLiquid platform, which provides circulating tumor DNA-based solutions including AlphaLiquid 100 and AlphaLiquid HRR for monitoring advanced cancer patients through detection of biomarkers across 118 cancer-related genes and 15 homologous recombination repair genes via a single blood test; CancerDetect for early detection of cancer recurrence post-surgery; and CancerFind for multi-cancer early detection screening of multiple tumor types with tissue-of-origin prediction. It also provides customized services for biopharma clinical trials, research applications, and healthcare checkups, focusing on clinical practice, oncology networks, real-time tumor response monitoring, and genotyping of cancer-related genes. Founded in 2018 and headquartered at 21F BYC Highcity Bldg A, 131 Gasandigital 1-ro, Seoul, South Korea, IMBdx operates primarily in the biotechnology sector targeting oncologists, hospitals, research institutions, biopharmaceutical companies, and patients across South Korea with expanding global reach. Recent developments include a strategic partnership expansion with AstraZeneca under the PROSPER 2.0 project in 2025 to enhance access to AlphaLiquid HRR for targeted therapies in metastatic prostate cancer in markets including Ukraine, Australia, Taiwan, Malaysia, Vietnam, Colombia, Mexico, Lebanon, United Arab Emirates, Saudi Arabia, and Kuwait; a 2024 collaboration with Inocras to introduce liquid biopsy diagnostics in the U.S. market; and advancements in CancerFind to detect up to 30 cancers by 2029 through a Korea ARPA-H funded project alongside presentations at AACR 2025 on CancerDetect and a partnership with Japan's MedPeer group.